Schofield et al. 77 Schofield JB, Krausz T, Stamp GW, Fletcher CD, Fisher C, Azzopardi JG. Ossifying fibromyxoid tumour of soft parts: immunohistochemical and ultrastructural analysis. Histopathology. 1993;22(2):101-12. http://dx.doi.org/10.1111/j.1365-2559.1993.tb00088.x. PMid:8454256. http://dx.doi.org/10.1111/j.1365-2559.19...
|
39/M |
Lip |
ovoid masses |
1.5 |
slow growing |
NA (ITS: present in 12/13 cases) |
0-1/10 HPFs |
No |
ITS: S100 10/12, Desmin 7/10, SMA 4/8, fast myosin and sarcomere actin: 1/6, cytokeratin 1/7, vimentin 3/3, GFAP 1/3, Leu-7 1/3, collagen IV 2/3, HMFG2 1/3, MSA−, PGP 9.5−, factor VIII−, CD34−, HMW, keratin−. |
NA |
NA (ITS: Follow-up were available on 8/13 (1-10 years – median: 7 years); NA (ITS: NED) |
41/M |
Buccal mucosa |
1.5 |
Williams et al.88 Williams SB, Ellis GL, Meis JM, Heffner DK. Ossifying fibromyxoid tumour (of soft parts) of the head and neck: a clinicopathological an immunohistochemical study of nine cases. J Laryngol Otol. 1993;107(1):75-80. http://dx.doi.org/10.1017/S0022215100122200. PMid:8445324. http://dx.doi.org/10.1017/S0022215100122...
|
67/F |
Left mandibular vestibule |
NA |
1.0 |
4 months |
NA (in their series: present in 6/8 cases) |
1-2/10 HPFs |
No |
ITS: S100 (3/5), NSE (3/5), GFAP (2/5), Vimentin (5/5), Leu-7 3/5, SMA (2/5), MSA (2/5), NFP (0/5), EMA (0/5), Cytokeratin (0/5). |
NA |
1.5 years; NED |
37/F |
Soft palate |
4.5 |
NA |
3 years; NED |
Mollaoglu et al.99 Mollaoglu N, Tokman B, Kahraman S, Cetiner S, Yucetas S, Uluoglu O. An unusual presentation of ossifying fibromyxoid tumor of the mandible: a case report. J Clin Pediatr Dent. 2007;31(2):136-8. http://dx.doi.org/10.17796/jcpd.31.2.f34037713m414l1u. PMid:17315811. http://dx.doi.org/10.17796/jcpd.31.2.f34...
|
13/M |
Left mandibular vestibule |
Hard, warm, painless mass covered by normal mucosa |
2.0 |
4 months |
Yes |
No |
No |
Vimentin +, SMA+ (focally), GFAP + (focally), S100−, EMA−, Pankeratin−, Desmin−, Leu-7−, CD34−. |
NA |
NA; NED |
Miettinen et al.11 Miettinen M, Finnell V, Fetsch JF. Ossifying fibromyxoid tumor of soft parts – a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature. Am J Surg Pathol. 2008;32(7):996-1005. http://dx.doi.org/10.1097/PAS.0b013e318160736a. PMid:18469710. http://dx.doi.org/10.1097/PAS.0b013e3181...
|
NA/NA |
Lower lip |
NA |
NA |
NA |
NA |
NA |
NA |
ITS: Vimentin (33/33), S100 (67/71), CD10 (22/28), Keratin (6/45), Collagen IV (3/23), Desmin 4/40, GFAP (3/41), EMA (1/47), SMA (1/43), CD34 (0/38), HMB45 (0/13) |
NA |
NA |
Sharif et al.1010 Sharif MA, Mushtaq S, Mamoon N, Khadim MT. Ossifying fibromyxoid tumor of oral cavity. J Coll Physicians Surg Pak. 2008;18(3):181-2. PMid:18460251. |
14/F |
Between buccal and gingival mucosa in the left anterior mandibular region |
Nodular swelling with reddish surface. |
4.0 |
3 months |
Yes |
<2/10 HPFs |
No |
Vimentin +, S100 +, EMA −, cytokeratins − |
NA |
NA |
Nonaka et al.1111 Nonaka CF, Pacheco DF, Nunes RP, Freitas RA, Miguel MC. Ossifying fibromyxoid tumor in the mandibular gingiva: case report and review of the literature. J Periodontol. 2009;80(4):687-92. http://dx.doi.org/10.1902/jop.2009.080535. PMid:19335090. http://dx.doi.org/10.1902/jop.2009.08053...
|
21/F |
Posterior mandibular gingiva |
Painless exophytic mass with a reddish and lobulated surface. |
6.0 |
6 months |
Yes |
No |
No |
Vimentin +, S100 +, SMA −, MAS −, GFAP − |
NA |
7 months; NED |
Ohtaet al.1212 Ohta K, Taki M, Ogawa I, et al. Malignant ossifying fibromyxoid tumor of the tongue: case report and review of the literature. Head Face Med. 2013;9(1):16. http://dx.doi.org/10.1186/1746-160X-9-16. PMid:23800162. http://dx.doi.org/10.1186/1746-160X-9-16...
|
26/M |
Dorsal tongue |
1st lesion: painless nodule 2nd lesion: painless mass with reddish and lobulated surface. |
1st lesion: 0.7; 2nd lesion: 2.0 |
1st lesion: 2 weeks; 2nd lesion: NA - gradually increasing |
Yes |
1st lesion: low; 2nd lesion: >2/10 HPFs |
1st lesion: No; 2nd lesion: High cellularity, scant pleomorphism |
Vimentin+, S100+ (partially), GFAP−, cytokeratins−, αSMA−, calponin−, desmin−, CD68−, CD34−, p63−, Ki67 (7%) |
|
1st lesion: 48 months; Recurrence (malignant OFMT – no metastasis) 2nd lesion: NA |
Titsinideset al.1313 Titsinides S, Nikitakis NG, Tasoulas J, Daskalopoulos A, Goutzanis L, Sklavounou A. Ossifying fibromyxoid tumor of the retromolar trigone: a case report and systematic review of the literature. Int J Surg Pathol. 2017;25(6):526-32. http://dx.doi.org/10.1177/1066896917705197. PMid:28436288. http://dx.doi.org/10.1177/10668969177051...
|
13/M |
Retromolar trigone area |
Painless mass, hard, nonmoveable covered by normal mucosa. |
0.8 |
7 months |
Yes |
No |
No |
Vimentin +, NSE+, MSA+, S100 −, GFAP −, SMA−, desmin −, AE1/AE3−, CD99−, CD34− |
NA |
48 months; NED |
index case |
45/F |
Buccal mucosa |
Painless nodule with smooth- surface. |
1.3 |
24 months |
Yes |
<2/10 HPFs |
Mild pleomorphism |
Vimentin +, S100 +, GFAP −, CD34 −, AE1/AE3 −, Calponin −, P63 −, Ki-67 5% |
Conserved |
7 years; NED |